Dataset related to article "Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events"

Source Flow Cytometry data for publication 10.1136/jitc-2024-010568 "Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events" Abstract: Immune checkpoint inhibitors (ICIs) revolutionized cancer therapy, yet require management of immune-related adverse events (irAEs). Fulminant myocarditis is a rare irAE, but lower-severity cardiac events are being reported more frequently, leading to an unmet need for irAE prevention, early diagnosis, and treatment, especially for long-life-expectancy patients. We recruited 57 patients, stratified according to therapy regime (monotherapy (30%) or combination (33%) cohort) or history of cardiac disease or presence of at least two cardiovascular risk factors other than prior or active smoking (cardiovascular cohort (37%)). We performed a complete cardiological assessment with clinical visit, 12-lead ECG, multiparametric cardiac MRI as well as peripheral blood mononuclear cell immunophenotyping, prior to ICI initiation and around 2 months later. ICI treatment was associated with a significant left ventricular ejection function (LVEF) reduction pre-ICI versus post-ICI treatment (60.1±8% to 58.1±8%, p=0.002, paired t-test) and more than 3% LVEF loss in a substantial proportion of patients (18; 32%). These patients also showed significantly higher T2 values (p=0.037, unpaired t-test), putative sign of cardiac edema. The loss of cardiac function did not differ among patients with different tumor types, therapy regimes or history of cardiac disease. Immunophenotyping analyses showed a reduction of programmed cell death protein 1 staining on both CD4+ and CD8+ T cells, and an upregulation of HLA-DR on CD8+ T cells. Using a very sensitive and comprehensive approach in patients unselected for cardiac history, we found a subclinical but significant LVEF decrease. These findings may inform ongoing discussions on optimal management of cardiac irAEs in patients undergoing ICI treatment and warrant further evaluation.用于期刊论文10.1136/jitc-2024-010568的流式细胞术（Flow Cytometry）原始数据集 《免疫检查点抑制剂治疗患者不良事件的心脏磁共振成像研究：一项心脏不良事件前瞻性队列研究》 摘要： 免疫检查点抑制剂（Immune Checkpoint Inhibitors, ICIs）彻底革新了癌症治疗范式，但同时需对免疫相关不良事件（immune-related adverse events, irAEs）进行管理。暴发性心肌炎是一类罕见的免疫相关不良事件，然而当前低级别心脏不良事件的报道愈发频繁，使得免疫相关不良事件的预防、早期诊断与治疗存在未被满足的临床需求，尤其针对预期寿命较长的患者。本研究共招募57例受试者，按照治疗方案（单药治疗组占30%，联合治疗组占33%）或合并心脏疾病史、除既往/当前吸烟外至少存在2项心血管危险因素的情况（心血管队列组占37%）进行分层。分别于免疫检查点抑制剂治疗开始前及治疗后约2个月时，对所有受试者完成全面的心脏学评估，包括临床就诊、12导联心电图、多参数心脏磁共振成像，以及外周血单个核细胞免疫表型分析。 免疫检查点抑制剂治疗与左心室射血功能（left ventricular ejection function, LVEF）的显著降低相关：治疗前与治疗后的LVEF分别为60.1±8%与58.1±8%（配对t检验，p=0.002），且有18例（32%）患者出现LVEF下降幅度超过3%的情况。此类患者的T2值亦显著升高（独立样本t检验，p=0.037），这被认为是心脏水肿的潜在标志性表现。不同肿瘤类型、治疗方案或心脏疾病史的受试者，其心功能下降程度无显著差异。免疫表型分析显示，CD4+和CD8+ T细胞表面的程序性死亡蛋白1（programmed cell death protein 1, PD-1）染色信号减弱，且CD8+ T细胞表面的HLA-DR表达上调。本研究在未预先筛选心脏病史的受试者中采用高灵敏度且全面的评估方案，发现了亚临床但具有统计学意义的LVEF下降。本研究结果可为当前针对免疫检查点抑制剂治疗患者心脏免疫相关不良事件的优化管理讨论提供参考依据，同时也有待开展进一步的研究验证。